nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—PLA2G4A—Acyl chain remodeling of CL—TAZ—dilated cardiomyopathy	0.031	0.0871	CbGpPWpGaD
Epirubicin—CHD1—cardiac ventricle—dilated cardiomyopathy	0.0195	0.124	CbGeAlD
Epirubicin—CHD1—myocardium—dilated cardiomyopathy	0.0183	0.116	CbGeAlD
Epirubicin—YWHAG—LKB1 signaling events—SIK1—dilated cardiomyopathy	0.0148	0.0417	CbGpPWpGaD
Epirubicin—AURKA—myocardium—dilated cardiomyopathy	0.0148	0.0937	CbGeAlD
Epirubicin—CHD1—heart—dilated cardiomyopathy	0.0128	0.0811	CbGeAlD
Epirubicin—AURKA—Aurora B signaling—DES—dilated cardiomyopathy	0.0126	0.0353	CbGpPWpGaD
Epirubicin—YWHAG—cardiac ventricle—dilated cardiomyopathy	0.012	0.0764	CbGeAlD
Epirubicin—YWHAG—myocardium—dilated cardiomyopathy	0.0113	0.0719	CbGeAlD
Epirubicin—CHD1—cardiac atrium—dilated cardiomyopathy	0.0109	0.0694	CbGeAlD
Epirubicin—AURKA—heart—dilated cardiomyopathy	0.0103	0.0654	CbGeAlD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—LAMA4—dilated cardiomyopathy	0.00885	0.0249	CbGpPWpGaD
Epirubicin—DHCR7—heart—dilated cardiomyopathy	0.00861	0.0547	CbGeAlD
Epirubicin—YWHAG—Translocation of GLUT4 to the plasma membrane—MYH7—dilated cardiomyopathy	0.00851	0.0239	CbGpPWpGaD
Epirubicin—YWHAG—Translocation of GLUT4 to the plasma membrane—MYH6—dilated cardiomyopathy	0.00851	0.0239	CbGpPWpGaD
Epirubicin—PLA2G4A—Enalapril—Lisinopril—dilated cardiomyopathy	0.0084	0.762	CbGdCrCtD
Epirubicin—YWHAG—heart—dilated cardiomyopathy	0.0079	0.0502	CbGeAlD
Epirubicin—AURKA—Regulation of PLK1 Activity at G2/M Transition—TUBB—dilated cardiomyopathy	0.00776	0.0218	CbGpPWpGaD
Epirubicin—DHCR7—cardiac atrium—dilated cardiomyopathy	0.00737	0.0468	CbGeAlD
Epirubicin—YWHAG—Loss of Nlp from mitotic centrosomes—TUBB—dilated cardiomyopathy	0.00723	0.0203	CbGpPWpGaD
Epirubicin—YWHAG—cardiac atrium—dilated cardiomyopathy	0.00676	0.0429	CbGeAlD
Epirubicin—AURKA—Regulation of PLK1 Activity at G2/M Transition—ALMS1—dilated cardiomyopathy	0.0065	0.0183	CbGpPWpGaD
Epirubicin—YWHAG—Centrosome maturation—TUBB—dilated cardiomyopathy	0.00641	0.018	CbGpPWpGaD
Epirubicin—YWHAG—Loss of Nlp from mitotic centrosomes—ALMS1—dilated cardiomyopathy	0.00606	0.017	CbGpPWpGaD
Epirubicin—PLA2G4A—heart—dilated cardiomyopathy	0.0059	0.0374	CbGeAlD
Epirubicin—YWHAG—Regulation of PLK1 Activity at G2/M Transition—TUBB—dilated cardiomyopathy	0.00588	0.0165	CbGpPWpGaD
Epirubicin—AURKA—G2/M Transition—TUBB—dilated cardiomyopathy	0.00583	0.0164	CbGpPWpGaD
Epirubicin—AURKA—Mitotic G2-G2/M phases—TUBB—dilated cardiomyopathy	0.00575	0.0162	CbGpPWpGaD
Epirubicin—YWHAG—Centrosome maturation—ALMS1—dilated cardiomyopathy	0.00537	0.0151	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of PLK1 Activity at G2/M Transition—ALMS1—dilated cardiomyopathy	0.00493	0.0139	CbGpPWpGaD
Epirubicin—AURKA—G2/M Transition—ALMS1—dilated cardiomyopathy	0.00488	0.0137	CbGpPWpGaD
Epirubicin—ABCC1—myocardium—dilated cardiomyopathy	0.00483	0.0307	CbGeAlD
Epirubicin—AURKA—Mitotic G2-G2/M phases—ALMS1—dilated cardiomyopathy	0.00482	0.0135	CbGpPWpGaD
Epirubicin—YWHAG—LKB1 signaling events—PSEN2—dilated cardiomyopathy	0.00474	0.0133	CbGpPWpGaD
Epirubicin—YWHAG—G2/M Transition—TUBB—dilated cardiomyopathy	0.00442	0.0124	CbGpPWpGaD
Epirubicin—YWHAG—Mitotic G2-G2/M phases—TUBB—dilated cardiomyopathy	0.00436	0.0122	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—DSG2—dilated cardiomyopathy	0.00434	0.0122	CbGpPWpGaD
Epirubicin—ABCC1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00405	0.0114	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00401	0.0113	CbGpPWpGaD
Epirubicin—YWHAG—G2/M Transition—ALMS1—dilated cardiomyopathy	0.0037	0.0104	CbGpPWpGaD
Epirubicin—YWHAG—Mitotic G2-G2/M phases—ALMS1—dilated cardiomyopathy	0.00365	0.0103	CbGpPWpGaD
Epirubicin—PLA2G4A—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.00361	0.0102	CbGpPWpGaD
Epirubicin—YWHAG—Membrane Trafficking—MYH6—dilated cardiomyopathy	0.00343	0.00963	CbGpPWpGaD
Epirubicin—YWHAG—Membrane Trafficking—MYH7—dilated cardiomyopathy	0.00343	0.00963	CbGpPWpGaD
Epirubicin—ABCC1—heart—dilated cardiomyopathy	0.00337	0.0214	CbGeAlD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—ACTC1—dilated cardiomyopathy	0.00306	0.00859	CbGpPWpGaD
Epirubicin—AURKA—Integrin-linked kinase signaling—RAC1—dilated cardiomyopathy	0.00304	0.00853	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00302	0.0085	CbGpPWpGaD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—RYR2—dilated cardiomyopathy	0.00297	0.00834	CbGpPWpGaD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—PLN—dilated cardiomyopathy	0.00289	0.00811	CbGpPWpGaD
Epirubicin—ABCC1—cardiac atrium—dilated cardiomyopathy	0.00288	0.0183	CbGeAlD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—RYR2—dilated cardiomyopathy	0.00287	0.00808	CbGpPWpGaD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—ITGB1—dilated cardiomyopathy	0.00286	0.00804	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00286	0.00804	CbGpPWpGaD
Epirubicin—YWHAG—p38 signaling mediated by MAPKAP kinases—RAF1—dilated cardiomyopathy	0.00281	0.00789	CbGpPWpGaD
Epirubicin—TOP2A—Methyltestosterone—Spironolactone—dilated cardiomyopathy	0.00262	0.238	CbGdCrCtD
Epirubicin—YWHAG—Apoptosis—DSP—dilated cardiomyopathy	0.0026	0.00731	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00255	0.00717	CbGpPWpGaD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—RPS6KB1—dilated cardiomyopathy	0.00255	0.00716	CbGpPWpGaD
Epirubicin—PLA2G4A—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.00252	0.00709	CbGpPWpGaD
Epirubicin—YWHAG—FoxO family signaling—SOD2—dilated cardiomyopathy	0.00245	0.0069	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.0024	0.00674	CbGpPWpGaD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—RAC1—dilated cardiomyopathy	0.0023	0.00646	CbGpPWpGaD
Epirubicin—YWHAG—FoxO family signaling—FASLG—dilated cardiomyopathy	0.00227	0.00639	CbGpPWpGaD
Epirubicin—ABCC1—S1P1 pathway—RAC1—dilated cardiomyopathy	0.00222	0.00624	CbGpPWpGaD
Epirubicin—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.00206	0.00433	CcSEcCtD
Epirubicin—Viral infection—Lisinopril—dilated cardiomyopathy	0.00206	0.00433	CcSEcCtD
Epirubicin—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00205	0.00431	CcSEcCtD
Epirubicin—Arthropathy—Lisinopril—dilated cardiomyopathy	0.00205	0.0043	CcSEcCtD
Epirubicin—Cough increased—Lisinopril—dilated cardiomyopathy	0.00203	0.00427	CcSEcCtD
Epirubicin—Alopecia—Spironolactone—dilated cardiomyopathy	0.00202	0.00425	CcSEcCtD
Epirubicin—Oliguria—Lisinopril—dilated cardiomyopathy	0.00202	0.00424	CcSEcCtD
Epirubicin—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00201	0.00423	CcSEcCtD
Epirubicin—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00195	0.00411	CcSEcCtD
Epirubicin—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00192	0.00403	CcSEcCtD
Epirubicin—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00191	0.00401	CcSEcCtD
Epirubicin—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00188	0.00396	CcSEcCtD
Epirubicin—Neck pain—Lisinopril—dilated cardiomyopathy	0.00188	0.00396	CcSEcCtD
Epirubicin—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00188	0.00396	CcSEcCtD
Epirubicin—YWHAG—mTOR signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00187	0.00527	CbGpPWpGaD
Epirubicin—Purpura—Furosemide—dilated cardiomyopathy	0.00187	0.00393	CcSEcCtD
Epirubicin—YWHAG—Class I PI3K signaling events mediated by Akt—RAF1—dilated cardiomyopathy	0.00186	0.00524	CbGpPWpGaD
Epirubicin—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00186	0.00391	CcSEcCtD
Epirubicin—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00186	0.00391	CcSEcCtD
Epirubicin—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00186	0.00391	CcSEcCtD
Epirubicin—AURKA—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00185	0.00521	CbGpPWpGaD
Epirubicin—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00185	0.00389	CcSEcCtD
Epirubicin—Lethargy—Furosemide—dilated cardiomyopathy	0.00184	0.00386	CcSEcCtD
Epirubicin—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00183	0.00384	CcSEcCtD
Epirubicin—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00182	0.00382	CcSEcCtD
Epirubicin—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00181	0.0038	CcSEcCtD
Epirubicin—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00181	0.0038	CcSEcCtD
Epirubicin—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00181	0.0038	CcSEcCtD
Epirubicin—YWHAG—Translocation of GLUT4 to the plasma membrane—RAC1—dilated cardiomyopathy	0.0018	0.00507	CbGpPWpGaD
Epirubicin—Malaise—Spironolactone—dilated cardiomyopathy	0.0018	0.00378	CcSEcCtD
Epirubicin—Cystitis—Lisinopril—dilated cardiomyopathy	0.0018	0.00378	CcSEcCtD
Epirubicin—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00178	0.00375	CcSEcCtD
Epirubicin—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00177	0.00371	CcSEcCtD
Epirubicin—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00176	0.00369	CcSEcCtD
Epirubicin—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00175	0.00367	CcSEcCtD
Epirubicin—PLA2G4A—p38 MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.00174	0.0049	CbGpPWpGaD
Epirubicin—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00169	0.00354	CcSEcCtD
Epirubicin—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00168	0.00354	CcSEcCtD
Epirubicin—Discomfort—Spironolactone—dilated cardiomyopathy	0.00168	0.00352	CcSEcCtD
Epirubicin—Dehydration—Furosemide—dilated cardiomyopathy	0.00167	0.00352	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—TUBB—dilated cardiomyopathy	0.00166	0.00466	CbGpPWpGaD
Epirubicin—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00166	0.00348	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00165	0.00465	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00165	0.00464	CbGpPWpGaD
Epirubicin—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00164	0.00346	CcSEcCtD
Epirubicin—Confusional state—Spironolactone—dilated cardiomyopathy	0.00164	0.00345	CcSEcCtD
Epirubicin—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00164	0.00344	CcSEcCtD
Epirubicin—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00163	0.00343	CcSEcCtD
Epirubicin—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00163	0.00342	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00162	0.00341	CcSEcCtD
Epirubicin—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00159	0.00335	CcSEcCtD
Epirubicin—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00159	0.00334	CcSEcCtD
Epirubicin—Abdominal distension—Furosemide—dilated cardiomyopathy	0.00157	0.00329	CcSEcCtD
Epirubicin—PLA2G4A—PDGF Pathway—RAC1—dilated cardiomyopathy	0.00156	0.00439	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00155	0.00437	CbGpPWpGaD
Epirubicin—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00155	0.00326	CcSEcCtD
Epirubicin—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00155	0.00325	CcSEcCtD
Epirubicin—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00154	0.00324	CcSEcCtD
Epirubicin—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00154	0.00323	CcSEcCtD
Epirubicin—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00153	0.00321	CcSEcCtD
Epirubicin—Eczema—Lisinopril—dilated cardiomyopathy	0.0015	0.00316	CcSEcCtD
Epirubicin—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.0015	0.00316	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—LMNA—dilated cardiomyopathy	0.00149	0.0042	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—EMD—dilated cardiomyopathy	0.00148	0.00415	CbGpPWpGaD
Epirubicin—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00146	0.00308	CcSEcCtD
Epirubicin—Somnolence—Spironolactone—dilated cardiomyopathy	0.00145	0.00304	CcSEcCtD
Epirubicin—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00144	0.00302	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00143	0.00403	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.00143	0.00402	CbGpPWpGaD
Epirubicin—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00142	0.00299	CcSEcCtD
Epirubicin—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00142	0.00298	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00141	0.00395	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0014	0.00295	CcSEcCtD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—ADRB1—dilated cardiomyopathy	0.0014	0.00394	CbGpPWpGaD
Epirubicin—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.0014	0.00295	CcSEcCtD
Epirubicin—PLA2G4A—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.0014	0.00392	CbGpPWpGaD
Epirubicin—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.0014	0.00293	CcSEcCtD
Epirubicin—AURKA—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00139	0.0039	CbGpPWpGaD
Epirubicin—Drowsiness—Furosemide—dilated cardiomyopathy	0.00139	0.00292	CcSEcCtD
Epirubicin—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00138	0.00291	CcSEcCtD
Epirubicin—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00138	0.0029	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00137	0.00289	CcSEcCtD
Epirubicin—Renal failure—Furosemide—dilated cardiomyopathy	0.00136	0.00287	CcSEcCtD
Epirubicin—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00136	0.00285	CcSEcCtD
Epirubicin—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00135	0.00284	CcSEcCtD
Epirubicin—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00135	0.00284	CcSEcCtD
Epirubicin—Diplopia—Lisinopril—dilated cardiomyopathy	0.00135	0.00284	CcSEcCtD
Epirubicin—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00134	0.00282	CcSEcCtD
Epirubicin—Sweating—Furosemide—dilated cardiomyopathy	0.00133	0.0028	CcSEcCtD
Epirubicin—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00131	0.00276	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—TTN—dilated cardiomyopathy	0.00131	0.00369	CbGpPWpGaD
Epirubicin—Face oedema—Lisinopril—dilated cardiomyopathy	0.0013	0.00274	CcSEcCtD
Epirubicin—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00129	0.00272	CcSEcCtD
Epirubicin—Urticaria—Spironolactone—dilated cardiomyopathy	0.00129	0.00272	CcSEcCtD
Epirubicin—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00129	0.0027	CcSEcCtD
Epirubicin—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.00128	0.0027	CcSEcCtD
Epirubicin—Ataxia—Lisinopril—dilated cardiomyopathy	0.00127	0.00267	CcSEcCtD
Epirubicin—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.00127	0.00266	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TUBB—dilated cardiomyopathy	0.00126	0.00353	CbGpPWpGaD
Epirubicin—Dehydration—Lisinopril—dilated cardiomyopathy	0.00126	0.00264	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00125	0.00352	CbGpPWpGaD
Epirubicin—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00123	0.00259	CcSEcCtD
Epirubicin—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00123	0.00259	CcSEcCtD
Epirubicin—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00122	0.00257	CcSEcCtD
Epirubicin—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00122	0.00257	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00122	0.00256	CcSEcCtD
Epirubicin—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00121	0.00254	CcSEcCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00121	0.00339	CbGpPWpGaD
Epirubicin—Visual impairment—Furosemide—dilated cardiomyopathy	0.0012	0.00252	CcSEcCtD
Epirubicin—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.0012	0.00252	CcSEcCtD
Epirubicin—Gastritis—Lisinopril—dilated cardiomyopathy	0.0012	0.00251	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00118	0.00331	CbGpPWpGaD
Epirubicin—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00118	0.00248	CcSEcCtD
Epirubicin—YWHAG—ErbB1 downstream signaling—RAC1—dilated cardiomyopathy	0.00117	0.00328	CbGpPWpGaD
Epirubicin—Asthma—Lisinopril—dilated cardiomyopathy	0.00117	0.00245	CcSEcCtD
Epirubicin—Influenza—Lisinopril—dilated cardiomyopathy	0.00117	0.00245	CcSEcCtD
Epirubicin—Eye disorder—Furosemide—dilated cardiomyopathy	0.00116	0.00245	CcSEcCtD
Epirubicin—Tinnitus—Furosemide—dilated cardiomyopathy	0.00116	0.00244	CcSEcCtD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—GJA1—dilated cardiomyopathy	0.00116	0.00326	CbGpPWpGaD
Epirubicin—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00116	0.00243	CcSEcCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.00115	0.00324	CbGpPWpGaD
Epirubicin—Pruritus—Spironolactone—dilated cardiomyopathy	0.00115	0.00242	CcSEcCtD
Epirubicin—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00114	0.00241	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—ACTN2—dilated cardiomyopathy	0.00114	0.0032	CbGpPWpGaD
Epirubicin—YWHAG—Calcium Regulation in the Cardiac Cell—ADRB2—dilated cardiomyopathy	0.00114	0.0032	CbGpPWpGaD
Epirubicin—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00114	0.00239	CcSEcCtD
Epirubicin—DHCR7—Metabolism—ANKRD1—dilated cardiomyopathy	0.00114	0.00319	CbGpPWpGaD
Epirubicin—Angiopathy—Furosemide—dilated cardiomyopathy	0.00113	0.00237	CcSEcCtD
Epirubicin—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00112	0.00236	CcSEcCtD
Epirubicin—YWHAG—mTOR signaling pathway—RAF1—dilated cardiomyopathy	0.00112	0.00316	CbGpPWpGaD
Epirubicin—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00112	0.00236	CcSEcCtD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—GJA1—dilated cardiomyopathy	0.00112	0.00315	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—EMD—dilated cardiomyopathy	0.00112	0.00315	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00112	0.00314	CbGpPWpGaD
Epirubicin—ABCC1—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00112	0.00313	CbGpPWpGaD
Epirubicin—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00111	0.00234	CcSEcCtD
Epirubicin—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00111	0.00234	CcSEcCtD
Epirubicin—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00111	0.00233	CcSEcCtD
Epirubicin—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00109	0.00229	CcSEcCtD
Epirubicin—Dysuria—Lisinopril—dilated cardiomyopathy	0.00109	0.00229	CcSEcCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.00109	0.00306	CbGpPWpGaD
Epirubicin—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00108	0.00228	CcSEcCtD
Epirubicin—Malnutrition—Furosemide—dilated cardiomyopathy	0.00108	0.00228	CcSEcCtD
Epirubicin—Erythema—Furosemide—dilated cardiomyopathy	0.00108	0.00228	CcSEcCtD
Epirubicin—Dizziness—Spironolactone—dilated cardiomyopathy	0.00108	0.00226	CcSEcCtD
Epirubicin—DHCR7—Metabolism—TAZ—dilated cardiomyopathy	0.00107	0.003	CbGpPWpGaD
Epirubicin—Flatulence—Furosemide—dilated cardiomyopathy	0.00107	0.00225	CcSEcCtD
Epirubicin—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00107	0.00224	CcSEcCtD
Epirubicin—PLA2G4A—Endothelins—RAC1—dilated cardiomyopathy	0.00106	0.00299	CbGpPWpGaD
Epirubicin—Weight increased—Lisinopril—dilated cardiomyopathy	0.00106	0.00223	CcSEcCtD
Epirubicin—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00106	0.00223	CcSEcCtD
Epirubicin—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00106	0.00222	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—ALMS1—dilated cardiomyopathy	0.00105	0.00296	CbGpPWpGaD
Epirubicin—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00105	0.00221	CcSEcCtD
Epirubicin—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00105	0.0022	CcSEcCtD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—EGFR—dilated cardiomyopathy	0.00105	0.00294	CbGpPWpGaD
Epirubicin—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00104	0.00219	CcSEcCtD
Epirubicin—PLA2G4A—PDGF Pathway—RAF1—dilated cardiomyopathy	0.00104	0.00291	CbGpPWpGaD
Epirubicin—Vomiting—Spironolactone—dilated cardiomyopathy	0.00103	0.00217	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00103	0.00217	CcSEcCtD
Epirubicin—PLA2G4A—AGE/RAGE pathway—RAC1—dilated cardiomyopathy	0.00103	0.00288	CbGpPWpGaD
Epirubicin—Rash—Spironolactone—dilated cardiomyopathy	0.00103	0.00216	CcSEcCtD
Epirubicin—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00102	0.00215	CcSEcCtD
Epirubicin—Renal failure—Lisinopril—dilated cardiomyopathy	0.00102	0.00215	CcSEcCtD
Epirubicin—Vision blurred—Furosemide—dilated cardiomyopathy	0.00102	0.00215	CcSEcCtD
Epirubicin—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00102	0.00214	CcSEcCtD
Epirubicin—Headache—Spironolactone—dilated cardiomyopathy	0.00102	0.00214	CcSEcCtD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—RAC1—dilated cardiomyopathy	0.00102	0.00285	CbGpPWpGaD
Epirubicin—Jaundice—Lisinopril—dilated cardiomyopathy	0.00101	0.00213	CcSEcCtD
Epirubicin—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00101	0.00213	CcSEcCtD
Epirubicin—Anaemia—Furosemide—dilated cardiomyopathy	0.001	0.00211	CcSEcCtD
Epirubicin—Sweating—Lisinopril—dilated cardiomyopathy	0.000998	0.0021	CcSEcCtD
Epirubicin—Agitation—Furosemide—dilated cardiomyopathy	0.000996	0.00209	CcSEcCtD
Epirubicin—Haematuria—Lisinopril—dilated cardiomyopathy	0.000992	0.00209	CcSEcCtD
Epirubicin—TOP2A—Gastric Cancer Network 2—EGFR—dilated cardiomyopathy	0.000986	0.00277	CbGpPWpGaD
Epirubicin—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000984	0.00207	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.000983	0.00276	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000983	0.00276	CbGpPWpGaD
Epirubicin—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000981	0.00206	CcSEcCtD
Epirubicin—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000976	0.00205	CcSEcCtD
Epirubicin—Vertigo—Furosemide—dilated cardiomyopathy	0.000974	0.00205	CcSEcCtD
Epirubicin—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000971	0.00204	CcSEcCtD
Epirubicin—Leukopenia—Furosemide—dilated cardiomyopathy	0.00097	0.00204	CcSEcCtD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000968	0.00272	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—VCL—dilated cardiomyopathy	0.000967	0.00272	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—SDHA—dilated cardiomyopathy	0.000966	0.00272	CbGpPWpGaD
Epirubicin—Nausea—Spironolactone—dilated cardiomyopathy	0.000966	0.00203	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—GJA1—dilated cardiomyopathy	0.000954	0.00268	CbGpPWpGaD
Epirubicin—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000951	0.002	CcSEcCtD
Epirubicin—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000937	0.00197	CcSEcCtD
Epirubicin—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000934	0.00196	CcSEcCtD
Epirubicin—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000927	0.00195	CcSEcCtD
Epirubicin—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000923	0.00194	CcSEcCtD
Epirubicin—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00092	0.00193	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000916	0.00193	CcSEcCtD
Epirubicin—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000916	0.00193	CcSEcCtD
Epirubicin—YWHAG—Apoptosis—FASLG—dilated cardiomyopathy	0.000905	0.00254	CbGpPWpGaD
Epirubicin—Dry mouth—Furosemide—dilated cardiomyopathy	0.000902	0.0019	CcSEcCtD
Epirubicin—Confusional state—Furosemide—dilated cardiomyopathy	0.000892	0.00188	CcSEcCtD
Epirubicin—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000885	0.00186	CcSEcCtD
Epirubicin—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000883	0.00186	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—TUBB—dilated cardiomyopathy	0.000879	0.00247	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—TMPO—dilated cardiomyopathy	0.000879	0.00247	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.000876	0.00246	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—FAS—dilated cardiomyopathy	0.000872	0.00245	CbGpPWpGaD
Epirubicin—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000871	0.00183	CcSEcCtD
Epirubicin—Shock—Furosemide—dilated cardiomyopathy	0.00087	0.00183	CcSEcCtD
Epirubicin—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000867	0.00182	CcSEcCtD
Epirubicin—Flushing—Lisinopril—dilated cardiomyopathy	0.000867	0.00182	CcSEcCtD
Epirubicin—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000866	0.00182	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000864	0.00243	CbGpPWpGaD
Epirubicin—Skin disorder—Furosemide—dilated cardiomyopathy	0.000859	0.00181	CcSEcCtD
Epirubicin—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000855	0.0018	CcSEcCtD
Epirubicin—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000848	0.00178	CcSEcCtD
Epirubicin—Anorexia—Furosemide—dilated cardiomyopathy	0.000843	0.00177	CcSEcCtD
Epirubicin—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000842	0.00177	CcSEcCtD
Epirubicin—Chills—Lisinopril—dilated cardiomyopathy	0.000838	0.00176	CcSEcCtD
Epirubicin—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000834	0.00175	CcSEcCtD
Epirubicin—Hypotension—Furosemide—dilated cardiomyopathy	0.000827	0.00174	CcSEcCtD
Epirubicin—Alopecia—Lisinopril—dilated cardiomyopathy	0.000825	0.00174	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.000824	0.00231	CbGpPWpGaD
Epirubicin—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000818	0.00172	CcSEcCtD
Epirubicin—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000813	0.00171	CcSEcCtD
Epirubicin—Erythema—Lisinopril—dilated cardiomyopathy	0.000813	0.00171	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000812	0.00228	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000807	0.00227	CbGpPWpGaD
Epirubicin—Flatulence—Lisinopril—dilated cardiomyopathy	0.000801	0.00168	CcSEcCtD
Epirubicin—Tension—Lisinopril—dilated cardiomyopathy	0.000798	0.00168	CcSEcCtD
Epirubicin—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000796	0.00167	CcSEcCtD
Epirubicin—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000794	0.00167	CcSEcCtD
Epirubicin—Nervousness—Lisinopril—dilated cardiomyopathy	0.00079	0.00166	CcSEcCtD
Epirubicin—Back pain—Lisinopril—dilated cardiomyopathy	0.000787	0.00165	CcSEcCtD
Epirubicin—Somnolence—Furosemide—dilated cardiomyopathy	0.000786	0.00165	CcSEcCtD
Epirubicin—TOP2A—Cell Cycle—EMD—dilated cardiomyopathy	0.000783	0.0022	CbGpPWpGaD
Epirubicin—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000782	0.00164	CcSEcCtD
Epirubicin—YWHAG—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.000774	0.00218	CbGpPWpGaD
Epirubicin—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000769	0.00162	CcSEcCtD
Epirubicin—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000766	0.00161	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000764	0.00161	CcSEcCtD
Epirubicin—Fatigue—Furosemide—dilated cardiomyopathy	0.000763	0.0016	CcSEcCtD
Epirubicin—Constipation—Furosemide—dilated cardiomyopathy	0.000756	0.00159	CcSEcCtD
Epirubicin—Pain—Furosemide—dilated cardiomyopathy	0.000756	0.00159	CcSEcCtD
Epirubicin—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000755	0.00159	CcSEcCtD
Epirubicin—Anaemia—Lisinopril—dilated cardiomyopathy	0.000752	0.00158	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000745	0.00209	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000736	0.00207	CbGpPWpGaD
Epirubicin—Malaise—Lisinopril—dilated cardiomyopathy	0.000733	0.00154	CcSEcCtD
Epirubicin—Vertigo—Lisinopril—dilated cardiomyopathy	0.000731	0.00154	CcSEcCtD
Epirubicin—Syncope—Lisinopril—dilated cardiomyopathy	0.000729	0.00153	CcSEcCtD
Epirubicin—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000729	0.00153	CcSEcCtD
Epirubicin—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000728	0.00153	CcSEcCtD
Epirubicin—YWHAG—Membrane Trafficking—RAC1—dilated cardiomyopathy	0.000727	0.00204	CbGpPWpGaD
Epirubicin—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—RAF1—dilated cardiomyopathy	0.000724	0.00204	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000723	0.00152	CcSEcCtD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000722	0.00203	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—LMNA—dilated cardiomyopathy	0.000722	0.00203	CbGpPWpGaD
Epirubicin—Palpitations—Lisinopril—dilated cardiomyopathy	0.000719	0.00151	CcSEcCtD
Epirubicin—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000715	0.0015	CcSEcCtD
Epirubicin—Cough—Lisinopril—dilated cardiomyopathy	0.00071	0.00149	CcSEcCtD
Epirubicin—PLA2G4A—Endothelins—RAF1—dilated cardiomyopathy	0.000706	0.00198	CbGpPWpGaD
Epirubicin—Urticaria—Furosemide—dilated cardiomyopathy	0.000703	0.00148	CcSEcCtD
Epirubicin—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000699	0.00147	CcSEcCtD
Epirubicin—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000699	0.00147	CcSEcCtD
Epirubicin—Chest pain—Lisinopril—dilated cardiomyopathy	0.000692	0.00146	CcSEcCtD
Epirubicin—Myalgia—Lisinopril—dilated cardiomyopathy	0.000692	0.00146	CcSEcCtD
Epirubicin—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000692	0.00146	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00069	0.00194	CbGpPWpGaD
Epirubicin—Anxiety—Lisinopril—dilated cardiomyopathy	0.00069	0.00145	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000688	0.00145	CcSEcCtD
Epirubicin—Discomfort—Lisinopril—dilated cardiomyopathy	0.000684	0.00144	CcSEcCtD
Epirubicin—PLA2G4A—AGE/RAGE pathway—RAF1—dilated cardiomyopathy	0.00068	0.00191	CbGpPWpGaD
Epirubicin—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000677	0.00142	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—TTN—dilated cardiomyopathy	0.000676	0.0019	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	0.000674	0.00189	CbGpPWpGaD
Epirubicin—Confusional state—Lisinopril—dilated cardiomyopathy	0.000669	0.00141	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—TMPO—dilated cardiomyopathy	0.000666	0.00187	CbGpPWpGaD
Epirubicin—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000664	0.0014	CcSEcCtD
Epirubicin—Oedema—Lisinopril—dilated cardiomyopathy	0.000664	0.0014	CcSEcCtD
Epirubicin—Infection—Lisinopril—dilated cardiomyopathy	0.000659	0.00139	CcSEcCtD
Epirubicin—Shock—Lisinopril—dilated cardiomyopathy	0.000653	0.00137	CcSEcCtD
Epirubicin—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000652	0.00137	CcSEcCtD
Epirubicin—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00065	0.00137	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000649	0.00182	CbGpPWpGaD
Epirubicin—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000648	0.00136	CcSEcCtD
Epirubicin—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000645	0.00136	CcSEcCtD
Epirubicin—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000642	0.00135	CcSEcCtD
Epirubicin—Asthenia—Furosemide—dilated cardiomyopathy	0.000635	0.00133	CcSEcCtD
Epirubicin—Anorexia—Lisinopril—dilated cardiomyopathy	0.000633	0.00133	CcSEcCtD
Epirubicin—TOP2A—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.00063	0.00177	CbGpPWpGaD
Epirubicin—Pruritus—Furosemide—dilated cardiomyopathy	0.000626	0.00132	CcSEcCtD
Epirubicin—Hypotension—Lisinopril—dilated cardiomyopathy	0.00062	0.0013	CcSEcCtD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—RAC1—dilated cardiomyopathy	0.000615	0.00173	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000612	0.00172	CbGpPWpGaD
Epirubicin—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000605	0.00127	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000605	0.00127	CcSEcCtD
Epirubicin—Insomnia—Lisinopril—dilated cardiomyopathy	0.0006	0.00126	CcSEcCtD
Epirubicin—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000596	0.00125	CcSEcCtD
Epirubicin—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000592	0.00124	CcSEcCtD
Epirubicin—Somnolence—Lisinopril—dilated cardiomyopathy	0.00059	0.00124	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000589	0.00166	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—ACTN2—dilated cardiomyopathy	0.000586	0.00165	CbGpPWpGaD
Epirubicin—Dizziness—Furosemide—dilated cardiomyopathy	0.000585	0.00123	CcSEcCtD
Epirubicin—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000584	0.00123	CcSEcCtD
Epirubicin—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000577	0.00121	CcSEcCtD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000574	0.00161	CbGpPWpGaD
Epirubicin—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000573	0.0012	CcSEcCtD
Epirubicin—Fatigue—Lisinopril—dilated cardiomyopathy	0.000572	0.0012	CcSEcCtD
Epirubicin—Constipation—Lisinopril—dilated cardiomyopathy	0.000568	0.00119	CcSEcCtD
Epirubicin—Pain—Lisinopril—dilated cardiomyopathy	0.000568	0.00119	CcSEcCtD
Epirubicin—Vomiting—Furosemide—dilated cardiomyopathy	0.000562	0.00118	CcSEcCtD
Epirubicin—Rash—Furosemide—dilated cardiomyopathy	0.000558	0.00117	CcSEcCtD
Epirubicin—Dermatitis—Furosemide—dilated cardiomyopathy	0.000557	0.00117	CcSEcCtD
Epirubicin—Headache—Furosemide—dilated cardiomyopathy	0.000554	0.00117	CcSEcCtD
Epirubicin—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000547	0.00115	CcSEcCtD
Epirubicin—YWHAG—Cell Cycle—LMNA—dilated cardiomyopathy	0.000547	0.00154	CbGpPWpGaD
Epirubicin—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.000543	0.00114	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000535	0.0015	CbGpPWpGaD
Epirubicin—YWHAG—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	0.000531	0.00149	CbGpPWpGaD
Epirubicin—Urticaria—Lisinopril—dilated cardiomyopathy	0.000527	0.00111	CcSEcCtD
Epirubicin—Nausea—Furosemide—dilated cardiomyopathy	0.000525	0.0011	CcSEcCtD
Epirubicin—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000525	0.0011	CcSEcCtD
Epirubicin—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000525	0.0011	CcSEcCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000524	0.00147	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000521	0.00146	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000517	0.00145	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000516	0.00145	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000506	0.00142	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—VCL—dilated cardiomyopathy	0.000498	0.0014	CbGpPWpGaD
Epirubicin—TOP2A—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000496	0.00139	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000495	0.00139	CbGpPWpGaD
Epirubicin—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000489	0.00103	CcSEcCtD
Epirubicin—Asthenia—Lisinopril—dilated cardiomyopathy	0.000476	0.001	CcSEcCtD
Epirubicin—Pruritus—Lisinopril—dilated cardiomyopathy	0.00047	0.000987	CcSEcCtD
Epirubicin—ABCC1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000468	0.00131	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000466	0.00131	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—TMPO—dilated cardiomyopathy	0.000466	0.00131	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000464	0.0013	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000455	0.00128	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000455	0.00128	CbGpPWpGaD
Epirubicin—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000454	0.000955	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000447	0.00126	CbGpPWpGaD
Epirubicin—Dizziness—Lisinopril—dilated cardiomyopathy	0.000439	0.000923	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000438	0.00123	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000428	0.0012	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000423	0.00119	CbGpPWpGaD
Epirubicin—Vomiting—Lisinopril—dilated cardiomyopathy	0.000422	0.000887	CcSEcCtD
Epirubicin—Rash—Lisinopril—dilated cardiomyopathy	0.000418	0.00088	CcSEcCtD
Epirubicin—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000418	0.000879	CcSEcCtD
Epirubicin—Headache—Lisinopril—dilated cardiomyopathy	0.000416	0.000874	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—CD36—dilated cardiomyopathy	0.000414	0.00116	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	0.000408	0.00115	CbGpPWpGaD
Epirubicin—Nausea—Lisinopril—dilated cardiomyopathy	0.000394	0.000829	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000392	0.0011	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—RAC1—dilated cardiomyopathy	0.00039	0.0011	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—ANKRD1—dilated cardiomyopathy	0.000385	0.00108	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—LMNA—dilated cardiomyopathy	0.000383	0.00107	CbGpPWpGaD
Epirubicin—YWHAG—Apoptosis—TNF—dilated cardiomyopathy	0.00037	0.00104	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—TAZ—dilated cardiomyopathy	0.000369	0.00104	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000368	0.00104	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—TAZ—dilated cardiomyopathy	0.000362	0.00102	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000336	0.000943	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—SDHA—dilated cardiomyopathy	0.000333	0.000937	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—SDHA—dilated cardiomyopathy	0.000327	0.000919	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000307	0.000864	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000291	0.000817	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—TAZ—dilated cardiomyopathy	0.000289	0.000812	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—GPX1—dilated cardiomyopathy	0.000262	0.000738	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—SDHA—dilated cardiomyopathy	0.000261	0.000734	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—RAF1—dilated cardiomyopathy	0.000259	0.000727	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CD36—dilated cardiomyopathy	0.000256	0.000718	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—ITGB1—dilated cardiomyopathy	0.00025	0.000703	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.00023	0.000647	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—AGT—dilated cardiomyopathy	0.00023	0.000647	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000219	0.000616	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—CD36—dilated cardiomyopathy	0.000213	0.0006	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000204	0.000573	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000204	0.000573	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—RAC1—dilated cardiomyopathy	0.000201	0.000565	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000199	0.000561	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000199	0.00056	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000194	0.000546	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.00019	0.000534	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000189	0.000532	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000183	0.000516	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000175	0.000492	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NPPA—dilated cardiomyopathy	0.00016	0.000449	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000159	0.000448	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000157	0.00044	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000155	0.000436	CbGpPWpGaD
Epirubicin—ABCC1—Disease—PSEN2—dilated cardiomyopathy	0.000155	0.000435	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000149	0.000418	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.00014	0.000393	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000136	0.000381	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—RAF1—dilated cardiomyopathy	0.000133	0.000375	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.00012	0.000338	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.00012	0.000338	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000115	0.000324	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000112	0.000315	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00011	0.00031	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000108	0.000305	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.26e-05	0.00026	CbGpPWpGaD
Epirubicin—ABCC1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	9.22e-05	0.000259	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—GPX1—dilated cardiomyopathy	9.06e-05	0.000255	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—GPX1—dilated cardiomyopathy	8.88e-05	0.00025	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—CD36—dilated cardiomyopathy	8.82e-05	0.000248	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—ADRB2—dilated cardiomyopathy	8.78e-05	0.000247	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—CD36—dilated cardiomyopathy	8.65e-05	0.000243	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—AGT—dilated cardiomyopathy	7.94e-05	0.000223	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—AGT—dilated cardiomyopathy	7.79e-05	0.000219	CbGpPWpGaD
Epirubicin—ABCC1—Disease—RAC1—dilated cardiomyopathy	7.78e-05	0.000219	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.65e-05	0.000215	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.55e-05	0.000212	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—GPX1—dilated cardiomyopathy	7.1e-05	0.000199	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—CD36—dilated cardiomyopathy	6.91e-05	0.000194	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RAC1—dilated cardiomyopathy	6.82e-05	0.000192	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—AGT—dilated cardiomyopathy	6.51e-05	0.000183	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—AGT—dilated cardiomyopathy	6.22e-05	0.000175	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.25e-05	0.000147	CbGpPWpGaD
Epirubicin—ABCC1—Disease—RAF1—dilated cardiomyopathy	5.16e-05	0.000145	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—RAF1—dilated cardiomyopathy	4.52e-05	0.000127	CbGpPWpGaD
Epirubicin—ABCC1—Disease—EGFR—dilated cardiomyopathy	3.54e-05	9.94e-05	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EGFR—dilated cardiomyopathy	3.1e-05	8.71e-05	CbGpPWpGaD
